Clinical Trial Results

CAR T-cell Therapy for HPV-Induced Metastatic Cervical Cancer Bookmark

Research paper from the Journal of Clinical Oncology, selected by Editor in Chief George Lundberg, MD, who notes:

CAR T-cell therapy has been approved by the U.S. Food and Drug Administration (FDA) for certain hematologic malignancies. This early study demonstrates its effectiveness in human papillomavirus (HPV)-induced metastatic cervical cancer as well.

Go to full article published by the Journal of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Regional Delivery of Mesothelin-Targeted CAR T-Cell Therapy Creates a Win for Solid Tumors Bookmark

Excerpt:

“In patients with malignant pleural disease, autologous mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy demonstrated clinical benefit with no significant toxicity, outcomes that may be due to the regional delivery of the CAR T cells to the intrapleural cavity rather than conventional systemic delivery. The phase I trial (ClinicalTrials.gov identifier: NCT02414269) results were presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting, held March 29–April 3 in Atlanta, Georgia (abstract CT036).”

Go to full article published by Cancer Network on April 10, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Experimental Drug Helps Women With Deadly Type of Breast Cancer Bookmark

Excerpt:

“An experimental drug has shown promise in extending the lives of women suffering from a particularly aggressive and deadly type of breast cancer, according to the results of a phase 2 trial.

“Right now, the standard treatment of chemotherapy for metastatic triple-negative breast cancer has not been very effective. That might change with the new drug, called sacituzumab govitecan, which combines an antibody with a chemotherapy drug to better target cancer cells.”

Go to full article published by U.S. News on Feb 20, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Targeted Radiation Therapy Yields High Response Rates in Metastatic Prostate Cancer Bookmark

Excerpt:

“The targeted radiation therapy Lutetium-177 PSMA-617 produced high response rates among men with prostate-specific membrane antigen-positive metastatic, castration-resistant prostate cancer, according to results of a single-arm, phase 2 trial scheduled for presentation at Genitourinary Cancers Symposium.

“The treatment also appeared well-tolerated among these men, whose disease had progressed after multiple standard therapies.”

Go to full article published by Healio on Feb 14, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Roche’s Kadcyla Cuts Risk of Breast Cancer Recurrence After Surgery Bookmark

Excerpt:

“Roche’s Kadcyla was significantly better than Herceptin at reducing the risk of breast cancer recurrence in certain patients with residual disease after surgery, according to new study findings presented at the San Antonio Breast Cancer Symposium.

“Data from the Phase III KATHERINE study show that Kadcyla (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death by 50% compared to Herceptin (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual disease following neoadjuvant therapy.”

Go to full article published by PharmaTimes on Dec 6, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Aggressive RT, Surgery Doubles OS in NSCLC With Limited Mets Bookmark

Excerpt:

“Aggressive local consolidation in stage IV non-small lung cancer (NSCLC) drastically improved overall survival over standard care in patients with up to three metastatic lesions, a small randomized study found.

“Among 49 patients whose disease had not progressed after initial systemic therapy, overall survival was 41.2 months in those treated with radiotherapy or surgery compared with 17.0 months in those on standard maintenance therapy (P=0.017), reported Daniel Gomez, MD, of MD Anderson Cancer Center in Houston, at a press briefing here at the American Society for Radiation Oncology (ASTRO) meeting.”

Go to full article published by MedPage Today on Oct 22, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Novartis Drug Cut Death Risk by 35 Percent in Gene Mutation Breast Cancer Bookmark

Excerpt:

“An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.

“The Swiss drugmaker’s BYL719, a so-called PI3K inhibitor also known as alpelisib, combined with hormone therapy fulvestrant boosted median progression-free survival (PFS) to 11 months, up from 5.7 months for patients who got only hormone therapy, the company said on Saturday.”

Go to full article published by Reuters on Oct 20, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

The Link Between Apalutamide and QOL in Non-Metastatic CRPC Bookmark

Excerpt:

“Adding apalutamide to androgen deprivation therapy (ADT) does not appear to harm health-related quality of life (HRQOL) in men with nonmetastatic castration-resistant prostate cancer (CRPC), according to new research published in Lancet Oncology.

“Previous research has showed that men in this patient population who received apalutamide had longer metastasis-free survival and a longer time to symptomatic progression compared with those who received placebo. This new study found that adding apalutamide still preserves HRQOL. Specifically, the group mean patient-reported outcome scores over time demonstrated HRQOL was maintained from baseline (initiation of apalutamide), and it was similar over time among men receiving apalutamide versus placebo.”

Go to full article published by Cancer Network on Oct 9, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Dual Neoadjuvant Checkpoint Blockade Feasible in Melanoma Bookmark

Excerpt from MedPage Today:

“Combination neoadjuvant immune checkpoint blockade therapy yielded promising outcomes in high-risk resectable melanoma, although toxicity was an issue, according to a phase II trial.

“The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) led to improved progression-free survival (PFS), distant metastasis-free survival (DMFS), and overall survival (OS) versus neoadjuvant nivolumab monotherapy in 23 patients with high-risk resectable melanoma, reported Jennifer A. Wargo, MD, of MD Anderson Cancer Center in Houston, and colleagues in Nature Medicine.”

Go to full article published by MedPage Today on Oct 11, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Pembrolizumab Plus Chemotherapy Prolongs OS, PFS for Metastatic Lung Cancer Bookmark

Excerpt from Healio:

“The addition of pembrolizumab to chemotherapy extended OS and PFS compared with chemotherapy alone among patients with metastatic, squamous, non-small-cell lung cancer, according to results of the randomized phase 3 KEYNOTE-407 trial presented at International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.

“The double-blind study included 559 treatment-naive patients with metastatic, squamous NSCLC. Patients who had symptomatic central nervous system metastases, a history of noninfectious pneumonitis that required the use of glucocorticoids, active autoimmune disease or who were receiving systemic immunosuppressive treatment were excluded.”

Go to full article published by Healio on Oct 1, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.